In some ways, the life sciences industry has been global for a long time. Companies founded over a century ago in Switzerland, Germany, and the U.K. are now worldwide household names, delivering vital therapies and devices to every corner of the globe. But the true globalization of the industry is a much more recent phenomenon. While large, multi-center trials have been commonplace for some time, advances in regulatory harmonization now enable manufacturers to seek simultaneous approvals in multiple territories. Digitization Across the Product Life Cycle Life sciences enterprises are operating at a scale and speed that would once have been unimaginable, and these changes have been enabled by another relatively recent development – the digitization of the industry. This trend is visible throughout product life cycles. Increasingly, studies are managed electronically, from trial master files to clinical outcome assessments. Authoring and review workflows for marketing materials are moving to more agile content management systems, preserving vital oversight mechanisms while significantly shortening time-to-market. Even regulators, never quick to embrace change, are now permitting or even requiring electronic submissions. AI for Life Science Business Localization We’re also seeing the beginnings of another wave of digital transformation, as artificial intelligence (AI) and machine learning (ML) technologies find applications in research and development. Pharmaceutical researchers are applying ML to the screening of molecular drug candidates. In diagnostic imaging, AI is showing growing promise as an aid to clinical interpretation. Clearly, these transformations have the potential to benefit patients. Getting drugs and devices to the market will always be a lengthy process, and for good reason. But as we saw during the COVID-19 pandemic, innovations in digital collaboration can have an enormous positive impact. Less obviously, by embracing digital solutions and AI, life sciences enterprises are converging with key service providers. This is especially true of language services, where automated digital workflows and AI-powered solutions have long since matured. These capabilities, coupled with deep domain expertise, are enabling the best language service providers to transcend their traditional roles. These providers are no longer just churning out words – they’re providing solutions that integrate deeply not just with development and regulatory activities but with the digital systems that now enable them. For life sciences enterprises, such providers can unlock enormous potential. AI-accelerated translation workflows can get expert-quality content to where it’s needed faster, whether that’s in a new market or in front of a regulator. But those workflows are also optimized for integration, which means they can be directly connected to key customer-side systems. Imagine: When your marketing materials clear the medical, legal, and regulatory (MLR) review cycle, you can initiate translation right from Veeva PromoMats. Your clinical team can do the same from Veeva Vault, and the translated study protocol or investigator brochure gets delivered back seamlessly to the system. And it’s not just translation. Your source content can also benefit from expert-led, AI-enabled profiling solutions. Life sciences enterprises – like all large organizations – produce all kinds of content, from corporate communications to internal training materials. What if all those content types could be recognized and automatically routed to the right workflows and specialist teams? Or what if you could have your lay person summaries rapidly profiled against specific regulatory standards for plain language? Well, it turns out all that is possible. Why not contact us to learn more?